Search Results for: Immunoterapia e terapia mirata per il carcinoma gastroesofageo avanzato

Il trattamento a Philadelphia, è la prima persona ad ottenerla

Fondamentali per scelta terapia, possibile evitare la chemio 

Sono 224mila i casi diagnosticati, ma si stimano circa 600mila

Ok Aifa a rimborsabilità farmaco che agisce a livello cerebrale

Sono 224mila i casi diagnosticati, ma si stimano circa 600mila

A Miami insignito del riconoscimento internazionale Phacilitate

In un mese 1,1 milioni di casi, ma forse 19 volte di più

Il direttore dell’istituto San Raffaele-Telethon per la terapia genica premiato per il suo fondamentale contributo allo sviluppo dei vettori genetici

In Italia colpite ogni anno 12.200 persone

Lim M, Franses JW, Imperial R, et al. EGFR/ERBB2 Amplifications and Alterations Associated With Resistance to Lenvatinib in Hepatocellular Carcinoma. Gastroenterology 2023;164:1006–1008.e3.

Objectives
Detailed simulation models are needed to assess strategies for prevention and treatment of hepatitis B virus (HBV) infection, the world’s leading cause of liver disease. We sought to develop and validate a simulation model of chronic HBV that incorporates virological, serological and clinical outcomes.

Methods
We developed a novel Monte Carlo simulation model (the HEPA-B Model) detailing the natural history of chronic HBV. We parameterised the model with epidemiological data from the Western Pacific and sub-Saharan Africa. We simulated the evolution of HBV DNA, ‘e’ antigen (HBeAg) and surface antigen (HBsAg). We projected incidence of HBeAg loss, HBsAg loss, cirrhosis, hepatocellular carcinoma (HCC) and death over 10-year and lifetime horizons. We stratified outcomes by five HBV DNA categories at the time of HBeAg loss, ranging from HBV DNA106 copies/mL. We tested goodness of fit using intraclass coefficients (ICC).

Results
Model-projected incidence of HBeAg loss was 5.18% per year over lifetime (ICC, 0.969 (95% CI: 0.728 to 0.990)). For people in HBeAg-negative phases of infection, model-projected HBsAg loss ranged from 0.78% to 3.34% per year depending on HBV DNA level (ICC, 0.889 (95% CI: 0.542 to 0.959)). Model-projected incidence of cirrhosis was 0.29–2.09% per year (ICC, 0.965 (95% CI: 0.942 to 0.979)) and HCC incidence was 0.06–1.65% per year (ICC, 0.977 (95% CI: 0.962 to 0.986)). Over a lifetime simulation of HBV disease, mortality rates were higher for people with older age, higher HBV DNA level and liver-related complications, consistent with observational studies.

Conclusions
We simulated HBV DNA-stratified clinical outcomes with the novel HEPA-B Model and validated them to observational data. This model can be used to examine strategies of HBV prevention and management.

Falcone (Simit), a volte necessario il ricovero o la terapia intensiva

Lieve aumento in terapia intensive, stabili i reparti pediatrici